Stapuldencel-T

司普登赛

Report date: 2025/02/02 20:00:08

Base Information

Drug NameStapuldencel-T

Drug Alias NameDendritic cell vaccine/Prostate cancerDCVAC-PCaDCVAC/PCa

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumBulgaria +[22]

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSotio

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSotio As

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Other Information

ATC CodeN/A